secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2021-11-03T23:59:59+00:00
Accession:  0001564590-21-053963
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotechnologies Q3 revenue up 50% to $39.5M, net loss widens; appoints new principal accounting officer
--------------------------------------------------------------------------------

- Q3 2021 revenue $39.5M (+50% YoY); sequencing revenue $22.1M (+96%), development revenue $17.4M (+16%).
- Net loss $56.0M vs $36.7M in Q3 2020; adjusted EBITDA loss $41.1M vs $28.4M.
- Full-year 2021 revenue guidance reaffirmed at $148-155M, ~54% growth at midpoint.
- clonoSEQ sequencing volume grew 47% YoY; launched enhanced assay for CLL including IGHV mutation status.
- Kyle Piskel appointed principal accounting officer; Chad Cohen remains CFO and principal financial officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000156459021053963/0001564590-21-053963-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000156459021053963/adpt-8k_20211028.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-053963

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer